Evolving aspects of liver transplantation for nonalcoholic steatohepatitis

Current Opinion in Organ Transplantation

Volumn 18, Issue 3, 2013, Pages 251-258

  Charlton, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

Liver transplantation; Metabolic syndrome; NASH; Obesity

Indexed keywords

EZETIMIBE; LORCASERIN;

ALCOHOL CONSUMPTION; BARIATRIC SURGERY; BODY MASS; DIABETES MELLITUS; DIET; GRAFT RECIPIENT; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; REVIEW; FATTY LIVER; RECURRENT DISEASE;

FATTY LIVER; HUMANS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; OBESITY; RECURRENCE;

MLCS; MLOWN;

EID: 84879914319     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283615d30     Document Type: Review

References (55)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434-438.
2. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12:1106-1110.
3. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140:124-131.
4. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141:1249-1253.
5. Perkins JD. Saying 'Yes' to obese living liver donors: short-term intensive treatment for donors with hepatic steatosis in living-donor liver transplantation. Liver Transpl 2006; 12:1012-1013.
6. Ratziu V, Voiculescu M, Poynard T. Touching some firm ground in the epidemiology of NASH. J hepatol 2012; 56:23-25.
7. Cho JY, Suh KS, Lee HW, et al. Hepatic steatosis is associated with intrahepatic cholestasis and transient hyperbilirubinemia during regeneration after living donor liver transplantation. Transpl Int 2006; 19:807-813.
8. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity [see comments]. Gastroenterology 1994; 107:1103-1109.
9. Ribeireiro T, Swain J, Sarr M, et al. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery: a prospective analysis. Obes Surg 2011.
10. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120:1183-1192.
11. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010; 52:913-924.
12. Cotler SJ, Vitello JM, Guzman G, et al. Hepatic decompensation after gastric bypass surgery for severe obesity. Dig Dis Sci 2004; 49:1563-1568.
13. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7:608-614.
14. Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004; 39:909-914.
15. Heimbach JK, Watt KD, Poterucha J, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. Am J Transplant 2013; 13:363-368.
16. Almutairi F, Peterson T, Molinari M, et al. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. Liver Transpl 2009; 15:504-508.
17. Watt KD, Pedersen RA, Kremers WK, et al. Evolution of causes and risk factors for mortality postliver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10:1420-1427.
18. Luzi L, Perseghin G, Regalia E, et al. Metabolic effects of liver transplantation in cirrhotic patients. J Clin Invest 1997; 99:692-700.
19. Modan-Moses D, Paret G. Leptin and transplantation: pieces are still missing in the puzzle. Isr Med Assoc J 2002; 4:207-208.
20. Man K, Zhao Y, Xu A, et al. Fat-derived hormone adiponectin combined with FTY720 significantly improves small-for-size fatty liver graft survival. Am J Transplant 2006; 6:467-476.
21. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002; 96:23-43.
22. Ozbay LA, Moller N, Juhl C, et al. Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. Br J Clin Pharmacol 2011; 73:536-545.
23. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9:311-326.
24. Veldt BJ, Watt KD, Thompson A, et al. Recipient IL28b polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Liver Transplant 2011; 17:S96-S100.
25. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40:1461-1465.
26. Sookoian S, Castano GO, Burgueno AL, et al. A nonsynonymous gene variant in adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J Lipid Res 2009; 50:2111-2116.
27. Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53:317-324.
28. Houlihan DD, Armstrong MJ, Davidov Y, et al. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens? Liver transplant 2011; 17:1292-1298.
29. Maor-Kendler Y, Batts KP, Burgart LJ, et al. Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases. Transplantation 2000; 70:292-297.
30. Dumortier J, Giostra E, Belbouab S, et al. Nonalcoholic fatty liver disease in liver transplant recipients: another story of 'seed and soil'. Am J Gastroenterol 2010; 105:613-620.
31. Singal AW, Watt KD, Heimbach JK, Charlton MR. Recurrence of metabolic syndrome and non-alcoholic steatohepatitis after liver transplantation: a comparative analysis. Hepatology 2012; 53(Suppl):Submitted to the AASLD 2012.
32. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27:103-107.
33. Vajro P, Fontanella A, Perna C, et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125:239-241.
34. Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970; 282:829-834.
35. Hickman IJ, Jonsson JR, Prins JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53:413-419.
36. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008; 6:1396-1402.
37. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6:998-1003.
38. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39:770-778.
39. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362:1675-1685.
40. Singal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic agents for liver disease. Liver Int 2011; 31:1432-1448.
41. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for nonalcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews. 2007:CD004996.
42. Seo S, Maganti K, Khehra M, et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transplant 2007; 13:844-847.
43. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart study randomized clinical trial. Am J Gastroenterol 2011; 106:71-77.
44. Belfort R, Harrison SA, Brown KA, et al. A placebo-controlled trial pioglitazone in subjects with nonalcoholic steatohepatitis. N Eng J Med 2006; 355:2297-2307.
45. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39:188-196.
46. Ye JM, Iglesias MA, Watson DG, et al. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 2003; 284:E531-E540.
47. Ip E, Farrell G, Hall P, et al. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology 2004; 39:1286-1296.
48. Miettinen M, Turpeinen O, Karvonen MJ. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1979; 42:370-371.
49. Stramler J. Clofibrate and niacin in coronary heart disease. J Am Med Assoc 1975; 231:360-381.
50. Mari M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006; 4:185-198.
51. Caballero F, Fernandez A, Matias N, et al. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. J Biol Chem 2010; 285: 18528-18536.
52. Mari M, Morales A, Colell A, et al. Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 2009; 11:2685-2700.
53. Mari M, Colell A, Morales A, et al. Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-kappaB activation. Gastroenterology 2008; 134:1507-1520.
54. Charlton M, Krishnan A, Viker K, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011; 301:G825-G834.
55. Wouters K, van Gorp PJ, Bieghs V, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 2008; 48:474-486.